Roche to invest CAD$190m in Canadian research site
It will include operations for all stages of global clinical trial research and create opportunities for r&d partnerships
The facility in Mississauga will be set up with additional funding of CAD$7.79m from Ontario’s Ministry of Economic Development and Trade. It will include operations for all stages of global clinical trial research and create opportunities for r&d partnerships with Ontario’s research and teaching hospitals, universities and other research institutions.
The Ontario government has also recently made similar investments in projects by Teva, GlaxoSmithKline and Pfizer.
Roche Canada said it chose Ontario because it offers the environment to support drug discovery and development, including an educated and capable workforce, and a business environment supported by a government that places a high strategic priority on life sciences.
‘As a leader in research and development, and biotechnology, we are extremely pleased to bring global pharmaceutical development opportunities to Ontario,’ said Ronnie Miller, president and ceo of Roche Canada.
‘We have built a respected clinical expertise within the Roche global network, and this new capability will firmly establish Roche Canada as a global hub for life sciences and biopharmaceuticals.’
Over the next five years, jobs in areas such as global trial and data management will be offered. The first positions have already been filled.
Roche says renovations to house the global site will begin during the summer, and several more positions will be filled by autumn. With this expansion, Roche will have more than 650 employees in Ontario.
Roche Canada was founded in 1931. The company employs approximately 900 people across the country, with its pharmaceuticals head office located in Mississauga and diagnostics division in Laval, Quebec.